Insta
Serum Institute Begins Phase Two And Three Bridging Trials Of Covid-19 Vaccine Candidate Covovax In India
Serum Institute of India (Pic Via Twitter)
In a boost to the national effort against the COVID-19 pandemic, the world's largest vaccine maker Serum Institute of India (SII) has started the phase two and three bridging trials of the Covovax Covid-19 vaccine candidate in India in a study that would involve 1,600 participants, reports Livemint.
The trials have begun at one of the sites in Pune, and at least one more site Delhi-based Hamdard Institute of Medical Sciences and Research is likely to begin screening for the vaccine candidate as early as upcoming Tuesday (30 March).
The company however has also reported, that its vaccine has an efficacy of 86.3 per cent against the UK mutant variant of the virus. On average, as per the company, the vaccine has an efficacy of 89.7 per cent.
Adar Poonawalla-led SII is already manufacturing pharmaceutical major AstraZeneca's vaccine under the name Covishield in India and is gearing to possibly launch Covovax by August. However, the company is planning to begin stockpiling the vaccine from April onwards to meet future demand.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest
